Analyst consensus rating
Artiva Biotherapeutics Analyst Rating: none
Direct answer
Artiva Biotherapeutics's consensus rating is none.
5 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $35.80.
Forecast evidence checked September 5, 2026.
Get free Artiva Biotherapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $11.19
- Average price target
- $35.80
- High price target
- $41.00
- Low price target
- $23.00
- Low target gap
- +105.5%
- Target upside
- +219.9%
- High target gap
- +266.4%
- Target range width
- 160.9%
- Consensus rating
- none
- Analysts
- 5
- Evidence date
- September 5, 2026
- Valid through
- September 12, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Artiva Biotherapeutics?
Artiva Biotherapeutics has a verified none consensus. The same dataset has an average price target of $35.80.
How far are Artiva Biotherapeutics's low and high targets from the recorded price?
The low target implies +105.5%, while the high target implies +266.4%.
How many analysts are included in Artiva Biotherapeutics's consensus?
The verified consensus includes 5 analysts.
How is Artiva Biotherapeutics's target upside or downside calculated?
The average target of $35.80 is divided by the recorded price of $11.19, then one is subtracted to produce +219.9%. This does not guarantee a future return.
When was Artiva Biotherapeutics's analyst forecast verified?
The data was verified on 2026-09-05. The dataset is valid through 2026-09-12.